Page 19 Bain Capital Helthcare
P. 19
19
Bain Capital
Healthcare
www.centrient.com
Investor: Bain Capital Private Equity
Centrient (formerly DSM Sinochem
Pharmaceuticals) is a CDMO focused
on beta-lactam antibiotics, next-
generation statins, and antifungals. Our
2018 investment focused on leveraging
Centrient’s healthcare expertise across
its global manufacturing footprint—
with facilities in The Netherlands,
Spain, India, Mexico, and China—to
drive sustainable growth and spark
innovation in the market combating
antibiotic resistance.
www.quvapharma.com
Investor: Bain Capital Private Equity
QuVa exemplifies our commitment
to operational improvement and
business building. Beginning as a
startup with two co-founders and a
partially completed facility, QuVa now
provides essential generic injectable
drugs in ready-to-use medical devices
to over half of US hospitals monthly.
We partnered with QuVa to improve
system-wide access and safety, which
led to improved quality, cost efficiency,
accelerated growth, and enhanced
healthcare delivery.
www.bplgroup.com
Investors: Bain Capital Private Equity,
UK Department of Health
In 2013, we acquired BPL from the
UK government to revitalize the
undercapitalized plasma-based
pharmaceuticals business. We
implemented strategic investments in
infrastructure, automation, and R&D,
expanding plasma collection by 50%
and creating over 750 new jobs. These
initiatives repositioned BPL as a global
leader in plasma products, exporting to
over 45 countries before we exited the
investment in 2016.
www.seranbio.com
Investors: Bain Capital Life Sciences,
Vivo Capital
Serán is an example of our active
investment in contract development
and manufacturing organizations
(CDMOs). Specializing in advanced
formulations, Serán serves
pharmaceutical and biotech companies
with development, analytical, and
clinical manufacturing services. Our
growth capital fuels Serán’s capabilities
and commercial facility expansion,
reinforcing its reputation as a cutting-
edge provider of tailored solutions.
www.fisvi.com/en
Investor: Bain Capital Private Equity
FIS is a leader in developing and pro-
ducing small-molecule active pharma-
ceutical ingredients (APIs) and inter-
mediates. Long owned by the Ferrari
family, we acquired a controlling stake
in 2023 and have worked to honor the
family’s commitment to excellence. Our
investment reflects our alignment with
firms delivering complex chemistry and
differentiated development capabilities.
FIS’s strong relationships with pharma-
ceutical and biotech customers enable
the worldwide distribution of life-saving
therapies and foster innovation across
the pharmaceutical supply chain.
Bain Capital
Healthcare
www.centrient.com
Investor: Bain Capital Private Equity
Centrient (formerly DSM Sinochem
Pharmaceuticals) is a CDMO focused
on beta-lactam antibiotics, next-
generation statins, and antifungals. Our
2018 investment focused on leveraging
Centrient’s healthcare expertise across
its global manufacturing footprint—
with facilities in The Netherlands,
Spain, India, Mexico, and China—to
drive sustainable growth and spark
innovation in the market combating
antibiotic resistance.
www.quvapharma.com
Investor: Bain Capital Private Equity
QuVa exemplifies our commitment
to operational improvement and
business building. Beginning as a
startup with two co-founders and a
partially completed facility, QuVa now
provides essential generic injectable
drugs in ready-to-use medical devices
to over half of US hospitals monthly.
We partnered with QuVa to improve
system-wide access and safety, which
led to improved quality, cost efficiency,
accelerated growth, and enhanced
healthcare delivery.
www.bplgroup.com
Investors: Bain Capital Private Equity,
UK Department of Health
In 2013, we acquired BPL from the
UK government to revitalize the
undercapitalized plasma-based
pharmaceuticals business. We
implemented strategic investments in
infrastructure, automation, and R&D,
expanding plasma collection by 50%
and creating over 750 new jobs. These
initiatives repositioned BPL as a global
leader in plasma products, exporting to
over 45 countries before we exited the
investment in 2016.
www.seranbio.com
Investors: Bain Capital Life Sciences,
Vivo Capital
Serán is an example of our active
investment in contract development
and manufacturing organizations
(CDMOs). Specializing in advanced
formulations, Serán serves
pharmaceutical and biotech companies
with development, analytical, and
clinical manufacturing services. Our
growth capital fuels Serán’s capabilities
and commercial facility expansion,
reinforcing its reputation as a cutting-
edge provider of tailored solutions.
www.fisvi.com/en
Investor: Bain Capital Private Equity
FIS is a leader in developing and pro-
ducing small-molecule active pharma-
ceutical ingredients (APIs) and inter-
mediates. Long owned by the Ferrari
family, we acquired a controlling stake
in 2023 and have worked to honor the
family’s commitment to excellence. Our
investment reflects our alignment with
firms delivering complex chemistry and
differentiated development capabilities.
FIS’s strong relationships with pharma-
ceutical and biotech customers enable
the worldwide distribution of life-saving
therapies and foster innovation across
the pharmaceutical supply chain.
